display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/adv melanoma (mML)
mML - L2 - all population
ipilimumab plus gp100 MDX010 Ipi plus gp100 vs gp100 MDX010 Ipi plus gp100 vs Ipi ...

Study type: